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Abstract
Introduction: The B-Natural study is a multicentre, multinational, observational study
of haemophilia B (HB) designed to increase understanding of clinical manifestations,
treatment and quality of life (QoL).
Aim: To characterise and compare QoL in HB across disease severity groups and indi-

Present address
Michelle Witkop, National Hemophilia
Foundation, New York, NY, USA

viduals with inhibitors to identify gaps in treatment.

Funding information
Sanofi; Biogen; Swedish Orphan Biovitrum

Methods: A total of 224 individuals from 107 families were enrolled from a total of
24 centres in North America (n = 16), Europe (n = 7) and Asia (n = 1). Of these, 68
(30.4%) subjects had severe (<1 IU/dL), median age 15.6 years, 114 (50.9%) moderate
(1–5 IU/dL), age 13.3 years, and 42 (18.8%) mild (>5–< 40 IU/dL), age 12.1 years, disease. Twenty-nine participants had inhibitors or a history of inhibitors. Three versions
of the EQ-5D instrument were used as a measure of QoL: proxy (ages 4–7), youth (ages
8–15) and self (age 16+). Each instrument included a visual analogue scale ranging from
100 (best health) to 0 (worst health) to assess current day’s health (EQ VAS). Range-ofmotion (ROM) for elbows, knees and ankles was assessed using a four-point scale, from
which a composite score was calculated.
Results: In all severity groups, a proportion of subjects showed less than optimal QoL.
The majority of the mild and moderate severe participants reported a normal EQ-5D
health profile (79% and 72%, respectively), whereas about half (47%) of the severe participants and only 13% of the inhibitor participants reported this profile.
Conclusion: The B-Natural study reveals impacted QoL in all disease severities of HB
including those with inhibitors. Unmet needs remain and include nonsevere HB.
KEYWORDS

EQ-5D, FIX, haemophilia B, inhibitor, prophylaxis, QoL

1

INTRODUCTION

come reports focus solely on HA with the occasional inclusion of a small
number of HB subjects. Recently, the B-HERO-S study investigating

Haemophilia B (HB) is caused by a deficiency or lack of clotting factor

a US cohort of 299 adult subjects with HB reported a high degree of

(F) IX.1 In contrast to HB, individuals with FVIII deficiency (haemophilia

unmet needs in HB with poorer health status in moderate haemophilia

A [HA]) are better studied mainly due to the fact that HA is approx-

compared to those with mild and severe cases. Anxiety/depression was

imately five times more common than HB (about one in 30,000 male

observed in >50% of adult respondents.4

births).2

Measures of disease control and outcomes of therapy include

The B-Natural study is a multicentre, multinational, observa-

an annualised bleed rate (ABR) and development of joint disease,

tional study of HB including both retro- and prospectively collected

usually assessed via physical scoring systems. More recently, patient

data, designed to increase understanding of clinical manifestations,

related outcomes (PRO) measures such as quality of life (QoL) have

treatment, QoL, inhibitor development, immune tolerance induction

become incorporated in medical parameters. Interestingly, QoL has

(ITI) outcome, renal function, and create a biorepository for future

been reported to be reduced not only in severe disease but also in

investigations.6 The objective of the current paper is to characterise

haemophilia.3–5

In fact, there are indications that

and compare QoL across disease severity groups and individuals with

individuals with severe haemophilia on prophylaxis may do better than

inhibitors in this large, international HB cohort to gain a deeper under-

moderate haemophilia patients who are not treated with prophylac-

standing of the patients’ health problems and to identify gaps in

tic regimens to the same extent.3 Due to the rarity of HB, most out-

treatment.

moderate and mild

3
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2

MATERIAL AND METHODS

US) and (3) the low number of participants in some of the sampled
regions/countries. As our focus is to provide descriptive information,

Demographics of the B-Natural cohort were recently described.6 Sub-

we focus on the analysis of the profile data themselves.

jects were eligible to participate if they had FIX deficiency and were

We summarised the severity of the EQ-5D profiles with the level

part of an affected sibling pair/group; and/or had a current or history

sum score (LSS) which treats each dimension’s level as a number rather

of inhibitor, defined as >.6 Bethesda units (BU). A total of 224 individu-

than a category.8 To produce the LSS each dimension’s level is added up

als from 107 families were enrolled from a total of 24 centres in North

to produce a score between 5 (best possible score) and 15 or 25 (worst

America (n = 16), Europe (n = 7) and Asia (n = 1). The recruitment rate

health state), for the three-level youth and five-level self and proxy ver-

per centre ranged from 17% to 100% with a median of 50%. Of these,

sions, respectively. Devlin et al. 20189 have shown the relationship of

68 (30.4%) subjects had severe (<1 IU/dL), 114 (50.9%) moderate (1–

the LSS with the English value set and demonstrated that as the LSS

5 IU/dL)) and 42 (18.8%) mild (>5–< 40 IU/dL) disease. Twenty-nine

increases (states worsen), the values decline; hence, the LSS is a valid,

participants had inhibitors or a history of inhibitors, all of whom had

albeit crude, measure of severity.

severe disease. The study included four female subjects, all with mild

The second part of the questionnaire is the EQ VAS. Each instru-

disease. Age distributions as measured by the median [25th; 75th per-

ment includes a visual analogue scale (VAS) to assess the participant’s

centile] for the severe, moderate and mild disease severity groups were

or proxy’s overall assessment of health (‘Health Today’) on a scale from

15.4 [11.0; 32.3], 13.3 [8.58; 20.3] and 12.1 [7.65; 20.8] years, respec-

100 (best health imaginable) to 0 (worst health imaginable). The EQ

tively, and 16.5 [8.08; 31.9] years for the group with inhibitors. Few

VAS is complementary to the EQ-5D profile as the overall score reflects

individuals above 50-years-old were enrolled whereas the age distri-

both the relative importance the participant/proxy places on the differ-

bution below 50 was rather even across the groups.

ent aspects of their health that are included in the EQ-5D descriptive
system and other dimensions of health that are not.

2.1

Health-related quality of life

The EQ-5D

instruments7

2.2

Joint assessment

were used to measure patient reported

health in a broad, ‘generic’ manner as this instrument is applicable to

Range-of-motion (ROM) for elbows, knees and ankles was assessed by

a wide range of health conditions and treatments. The five-dimension

qualified treatment centre staff trained in joint measurements. A four-

EQ-5D-5L self-administered health questionnaire was used for partic-

point scale was used: 0 = No loss of total full range of motion (FROM);

ipants 16+ years of age, the EQ-5D-5L proxy version was completed

1 = Loss of < 10% of total FROM; 2 = Loss of 10–33⅓% of total FROM;

by a caregiver for participants aged 4–7 years, and the EQ-5D-Y youth

3 = Loss of >33⅓% of total FROM. This method was chosen primar-

version for those 8–15 years of age. Using a set of levels ranging from

ily for feasibility and the expectation that each centre would be able

1 to 5, with 1 being the best and 5 the worst, the EQ-5D-5L self-

to reliably provide these measurements. A composite score was calcu-

administered and proxy versions assess the dimensions of mobility,

lated for participants without any missing FROM scores by summing

self-care, usual activity, pain/discomfort and anxiety/depression (given

the FROM scores for each joint according to the following formula:

in this order as EQ-5D profiles in Section 3). The EQ-5D-Y youth verComposite Score = Ankleleft + Ankleright + Kneeleft + Kneeright

sion uses three levels for each dimension.
The EQ-5D questionnaire consists of two parts. The first is the EQ-

+ Elbowleft + Elbowright

5D descriptive system. Participants are asked to check boxes to indicate the level of problem they experience on each of the five dimensions. The combination of these checked boxes under each dimension
describes that participant’s EQ-5D self-reported health state, often

The composite score ranges from 0 (no loss of FROM in any joint
evaluated) to 18 (loss of >33⅓ in all joints).

called an ‘EQ-5D profile’.
The EQ-5D profile data can be supplemented by using a ‘scoring’

2.3

Statistical analyses

or ‘weighting’ system to convert profile data to a single number: EQ5D values also sometimes referred to as the EQ-5D index. The index

All statistical analyses were performed in the R language.10 Descrip-

value reflects how good or bad a health state is according to the prefer-

tive statistics including means (standard deviations) and medians [25th

ences of the general population of a country/region and facilitate the

percentile; 75th percentile] were used. Relationships between continu-

calculation of quality-adjusted life years (QALYs). The preferences of

ous variables were examined by means of exploratory univariate linear

the general population of a country/region for different health states

regression and Pearson correlation coefficients. Interpretation of the

represent the societal perspective. We were unable to create EQ-5D

correlation coefficients’ strengths followed the naming conventions

indices in this study because (1) value sets were unavailable for three

of Chan.11 To test whether the number of subjects reporting a prob-

of the seven countries/regions, (2) even for countries with available

lem differed by severity group, Fisher’s exact tests were used. Differ-

value sets, our patient population is not representative of the general

ences in QoL scores between severity and/or treatment groups were

population (e.g., large Amish study population at several sites in the

assessed using Wilcoxon tests. Intrasibling correlations were not taken

4
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into account in the statistical analyses and will be explored in a separate

health profiles were reported across all subjects (30 unique profiles

paper.

in the self/proxy version respondents, and 16 in the youth respondents). The top three most frequently reported profiles represented
75% of all respondents (profiles 11111, 11112, 11121). A large pro-

2.4

Ethical approval

portion of observations were accounted for by profile 11111 (no problems in any dimension). The majority of the mild and moderate severe

The procedures followed were approved by the ethical committees in

participants reported this 11111 profile (79% and 72%, respectively),

each participating centre. B-Natural is registered at ClinicalTrials.gov

whereas about half (47%) of the severe participants and only 13% of

(NCT02502409).

the inhibitor participants reported this profile.
Dichotomised (problems/no problems), pooled self, proxy and youth
EQ-5D responses are shown in Figure 1. All severity groups, includ-

3

RESULTS

ing those with an inhibitor, included subjects reporting problems in
most every dimension of the EQ-5D (Figure 1A). Inhibitor participants

3.1

QoL questionnaires

reported lower QoL in all domains compared to the groups without an
inhibitor, and severe subjects without inhibitor had consistently worse

Table 1 provides a summary of completion for the age-specific EQ-5D

QoL than moderate or mild HB (Figure 1B). At least 50% of inhibitor

QoL instruments by disease severity group. Fifteen participants were

participants reported problems in the mobility (54%), pain/discomfort

too young, <4 years of age, to complete the instrument, two partic-

(58%) and anxiety/ depression (50%) domains. A rather high propor-

ipants had a missing EQ-5D questionnaire for unknown reasons and

tion of these inhibitor participants reported problems with self-care

one inhibitor participant had incomplete data (not shown in table);

(29%) and usual activities (46%). As illustrated in Figure 1B, the severe

these participants were excluded from the analyses. Participants with

HB group followed a similar pattern as those with inhibitors but with

inhibitors were slightly older than those in the noninhibitor group, thus

a slightly lower proportion reporting problems in each domain and

were more likely to complete the self-administered EQ-5D than the

with relatively lower proportions of reported problems in the anxi-

proxy or youth versions. Moderate HB represented the largest group

ety/depression and mobility domains. The moderate and mild severity

(n = 114), whereas severe and mild participants were fewer (39 and

HB participants appeared very similar in pattern although the mod-

42, respectively). The smallest group (n = 29) comprised those with

erate participants seemed to report relatively more problems in the

inhibitors, all of whom had severe disease. Complete cohort demo-

pain/discomfort domain.
The mild and moderate HB participants have similar LSS distribu-

graphics and clinical characteristics can be found in our recent study
publication.6

tions with a median and interquartile range (IQR) of 5.0 or 5.5.0–6.0
for the moderate group in the self/proxy respondents, reflecting that
the nonsevere participants mainly reported no problems in any of the

3.2

EQ-5D profiles

dimensions (in line with the majority reporting the 11111 health profile noted above). The severe HB participants had a higher median and

Supplemental Tables S1a and S1b list the frequencies of the observed

more variation (median = 6, IQR = [5,8] in both the self/proxy and

health profiles by severity group for subjects that filled out the 5-level

youth respondents) whereas the inhibitor participants had the high-

EQ-5D self or proxy version and the 3-level EQ-5D youth, respec-

est median (self/proxy: median = 8.0, IQR = [6,11]; youth: median = 7,

tively. Of the many possible health profiles, a total of only 39 unique

IQR = [6,10]).

TA B L E 1

Summary of completion for versions of the EQ-5D and EQ VAS QoL instruments by HB severity group
No inhibitor
Inhibitor
n = 29a

Severe (<1%)
n = 39a

14 (48%)

12 (31%)

44 (39%)

18 (43%)

Proxy

3 (10%)

7 (18%)

20 (18%)

8 (19%)

Youth

7 (24%)

17 (44%)

42 (37%)

15 (36%)

Missingb

5 (17%)

3 (8%)

8 (7%)

1 (2%)

24 (83%)

36 (92%)

104 (91%)

38 (90%)

Characteristic

N

EQ-5D version

224

Self

EQ VAS

224

HB, haemophilia B; QoL, quality of life; VAS, visual analogue scale.
a
Statistics presented: n (%).
b
Includes 15 subjects who did not meet minimum age requirement of 4 years old.

Moderate (1%–5%)
n = 114a

Mild (>5%)
n = 42a

5
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(A)

0.8

p<0.001

p<0.001

p<0.001

p<0.001

p<0.001

(B)
Usual act

Proportion reporting problem

100%
14

0.6

13

50%

12
11

Anx/Depr

Self care

16

0%

0.4

11

11

7

8
0.2

6

15

4
5

3

0.0
Mobility

3

7 3

Pain/Disc

Anx/Depr

6 2

Pain/Disc

Mobility

0

Self care

Severity Group

Usual act

Inhibitor

No Inhibitor: Severe (<1%)

No Inhibitor: Moderate (1−5%)

No Inhibitor: Mild (>5%)

F I G U R E 1 Proportion of subjects reporting impaired QoL by HB severity group and QoL score dimension. (A) Bar chart showing the
proportion of participants reporting a problem within severity group based on dichotomised, combined EQ-5D-5L response. Bars are displayed for
all five response dimensions. Number of subjects is denoted above each bar, as well as significance levels from Fisher exact tests comparing
between severity groups within each dimension. (B) Radar plot showing percentages of participants with impaired health-related QoL by severity
group. Similar to (A), QoL scores are based on dichotomised, combined EQ-5D-5L responses within response dimension. HB, haemophilia B; QoL,
quality of life

3.3

EQ VAS

interval [CI]: [−.59, −.37]; p < .001). Significant poor and fair negative
correlations were observed between EQ VAS and both BMI (−.19, 95%

Inhibitor participants tended to report lower EQ VAS scores (M = 76.4,

CI [−.32, −.06]; p = .006) and age (−.38, 95% CI [−.49, −.26]; p < .001).

SD = 20.2) than the other groups followed by the severe HB par-

Additionally, age and composite joint score were positively correlated

ticipants (M = 85.9, SD = 14.4). In turn, the moderate and mild HB

(.54, 95% CI [.44–.63]; p < .001). Although correlations were statisti-

cases had higher scores than the severe cases (M = 94.9, SD = 8.06

cally significant, their clinical value for a single subject is uncertain.

and M = 95.3, SD = 7.89, respectively). Additionally, and as expected
(since the EQ-5D is complementary to the EQ-5D health profile), we
observed significant negative correlations within each severity group

4

DISCUSSION

between the EQ VAS and the LSS summary scores.
Participants reporting no problems on any of the EQ-5D dimen-

The B-Natural study represents a large, international cohort of FIX

sions have higher EQ VAS scores across all ages than those reporting

deficient participant spanning all severities including inhibitor partic-

problems. However, the EQ VAS declines with age in a similar fash-

ipants, with a broad age range spanning 1–50 years with a few indi-

ion in those reporting problems and those that do not. No significant

viduals >50. This diverse study population provides an opportunity to

differences were observed when comparing EQ VAS scores by treat-

compare QoL in a broad spectrum of different clinical entities of HB

ment received (continuous replacement therapy/prophylaxis versus

reflecting real-world experience. Using EQ-5D health profiles and EQ

on-demand treatment) within severity groups (Figure 2). When com-

VAS, we found that participants with inhibitors reported lower QoL

paring between severity groups (pooled prophylaxis and on-demand

compared to the those without inhibitors. Participants with severe dis-

treatments), significantly lower scores were observed in the severe HB

ease without inhibitors had worse QoL scores than those with mod-

group when compared to moderate and mild HB (p < .001). Scores were

erate and mild HB. Severe participants on prophylaxis tended to have

not significantly different between the moderate and mild groups. It

higher reported QoL compared to those treated on-demand and had

should be noted that the sample sizes of several of the groups were

scores similar to those with moderate and mild disease of whom the

small and firm conclusions cannot be drawn.

majority were treated on-demand. We also observed that increased

The EQ VAS score was negatively correlated with the composite

joint score (i.e. presence of joint disease), high BMI and older age has

joint score (only including individuals without missing data, n = 202)

a significant, negative correlation with QoL by EQ VAS. These findings

with a fair Pearson correlation coefficient of −.49 (95% confidence

are close to what has been reported for HA12 and again underscores

6
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NS
p<0.001
p<0.001

EQ VAS

100

Treatment
Prophylaxis

80

On−demand

60

23 13

8 96

2 36

No Inhibitor: Severe (<1%)

No Inhibitor: Moderate (1−5%)

No Inhibitor: Mild (>5%)

F I G U R E 2 Distribution of EQ VAS scores by HB severity group and treatment received. Boxes represent the interquartile range, with a line for
the median. Whiskers extend to 1.5 times the IQR. Significance levels from Wilcoxon tests comparing between severity groups are annotated. All
comparisons between treatments within severity groups were not significant and are not displayed in the figure. HB, haemophilia B; IQR,
interquartile range; NS, not significant; VAS, visual analogue scale

the importance of long-term surveillance and individualised treatment

population norms. The low number of subjects in our study prevents

of haemophilia including both HA and, as shown here, HB. Importantly,

firm conclusions. Our findings in moderate HB support prior reports

some participants with moderate and mild HB had lower than opti-

from studies in both HA and HB that show that moderate haemophilia

mal QoL and presence of joint disease, and those with severe HB on

may have decreased QoL compared to severe haemophilia where treat-

prophylaxis did not differ from nonsevere HB. These findings indicate

ment with prophylaxis is more commonly used. In the B-Hero study,

that in the B-Natural cohort (1) prophylaxis alone is not sufficient for

299 subjects with HB were evaluated using several questionnaires

normalising QoL and (2) individuals with nonsevere HB may require

including EQ-5D-5L with VAS.4 Pain, functional impairment and anxi-

additional treatment, that is more intense/earlier start of prophylaxis

ety/depression were present in higher than expected levels in HB and a

and psycho-social support to normalise their QoL relative to an age-

large proportion of individuals with nonsevere HB with reduced health

matched, nondiseased population. This is strengthened by the previ-

status suggested significant unmet needs in this population. In the

ously reported pattern of joint disease in B-Natural6 and significant

study by Lindvall et al.,3 144 adult participants with HA or HB (22.9% of

correlation between joint disease and QoL in the present study. In a

total population had HB) were evaluated for QoL using the SF-36 ques-

recent report by Jiang et al,13 US population norms for the EQ-5D-

tionnaire. In the 35–64 years age group QoL was significantly reduced

5L were reported. Their respondents were representative of the gen-

in a few of the domains (general health, mental health). Participants

eral US adult population with a mean age of 46.9 years in the face-

with moderate disease reported more impairment in general health

to-face acquired sample (similar results were obtained in the online

and mental health compared to those with severe or mild haemophilia.

sample); these subjects are considerably older than the ones in our

The notion that individuals with moderate haemophilia may benefit

cohort. They did not find any gender difference but an age dependent

from prophylactic therapy has been raised by several studies.,14–16 The

decline in utility and VAS was observed up till the 45–54 year old cohort

PROBE study12 also showed a significantly impaired QoL in partici-

when norms levelled out. The VAS score was 84.9 in their youngest

pants with nonsevere haemophilia. The PROBE questionnaire includes

cohort (<25 years) whereas we found scores ≥90 in our nonsevere

three domains: general health, specific haemophilia A or B related

subjects. In the Jiang paper, the prevalence of any problems in each

questions and the third domain includes the EQ-5D-5L as well as EQ

dimension increased with advancing age except for anxiety/depression.

VAS. Of the 236 respondents with haemophilia, 102 had mild and 134

In our cohort pain/discomfort stands out in moderate haemophilia and

moderate disease of whom the vast majority had HA. The PROBE study

is twice as common (14% vs. 6.6%) as anxiety/depression compared to

results corroborate other studies in that nonsevere haemophilia is not

rather similar results between these dimensions in the study by Jiang

optimally treated in terms of joint disease outcome and support the

et al. Considering the caveat that our study is different from theirs in

finding in our study that QoL is impaired in this group of participants

several respects and results are presented differently, it seems as if

we can state that prophylaxis affects joint health, that is the physical

pain/discomfort is dominating in moderate haemophilia compared to

domain in EQ-5D, and is still important for the well-being of the patient.

7
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Nonsevere haemophilia is often a ‘forgotten’ disorder.5 The preva-
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